InVivo seeks FDA humanitarian use exemption for its spinal scaffold

December 17, 2012 by MassDevice staff

InVivo Therapeutics seeks FDA humanitarian use device exemption for its biopolymer scaffolding product in treatment of non-severing spinal cord injuries.

invivo logo

InVivo Therapeutics (OTC:NVIV) is seeking FDA approval for a humanitarian use device designation for its biopolymer scaffolding product in treatment of traumatic spinal cord injuries.

The Cambridge, Mass.-based firm expects to begin a clinical trial of the scaffolding in acute spinal cord injuries early next year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp